EOE Archives

Comic-book-style illustration highlighting pharma, space and AI investment themes: a Bayer research lab in Ohio, a SpaceX rocket launching from an Ohio-inspired Starbase, and Eupraxia displayed over an AI-powered global network, beneath the headline “Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up.”

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

by John F. Heerdink, Jr. October 3, 2026 234Views 0Likes

The Market’s Growth Engines Are Getting Physical Wall Street has spent years rewarding promises around artificial intelligence, advanced medicine and space infrastructure. This week, the narrative acquired something investors usually appreciate even more: concrete evidence of execution. Bayer AG (OTC: BAYRY) is…

🚀 Register to Join “Food Shouldn’t Hurt: EoE, Eupraxia, and a Promising New Treatment Approach” – (Friday, August 21 at 8:30am PT)

by John F. Heerdink, Jr. August 20, 2026 370Views 0Likes

Tribe Public (www.TribePublic.com) is welcoming James A. Helliwell, M.D., Co-Founder and Chief Executive Officer of Eupraxia Pharmaceuticals (NASDAQ: EPRX), for a timely discussion of Eupraxia’s work in EoE, its proprietary Diffusphere™ drug-delivery platform, and the potential opportunity ahead. Dr. Helliwell brings an…

The Million‑Patient Question: Is Eupraxia’s EP‑104GI Ready To Turn EoE Endoscopy Into A Business Model? -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. July 30, 2026 286Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) wrapped up its KOL event today with a clear message for Wall Street and the GI community: EP‑104GI is not just another esophageal steroid, it is being architected to live comfortably inside real‑world upper endoscopy practice for eosinophilic…

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. July 20, 2026 226Views 0Likes

Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is quietly setting up one of the more intriguing biotech inflection points on Wall Street as it marches toward Phase 2b data for EP‑104GI in eosinophilic esophagitis (EoE) this December, with investors increasingly framing the “bar” in…

Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. June 19, 2026 622Views 0Likes

Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors,…

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. May 18, 2026 531Views 0Likes

Eupraxia’s (NASDAQ: EPRX) current analyst chorus post their most recent First Quarter 2026 Financial Results report is now singing from the same hymn book: this is a late-stage GI platform story with cash in the bank, near-term catalysts, and price targets that…

From Weekly Jabs to Yearly Scopes: Why Eupraxia’s EP‑104GI Might Have Sanofi Checking Its Calendar – ( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. May 6, 2026 523Views 0Likes

Eupraxia’s (NASDAQ: EPRX) latest data drop puts eosinophilic esophagitis (EoE) firmly at center stage, with fresh endoscopic and long‑term clinical results suggesting EP‑104GI could emerge as a once‑yearly, procedure‑based alternative to chronic biologic regimens such as Sanofi’s (SNY) multi-billion dollar weekly-injectable drug…

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

by John F. Heerdink, Jr. April 28, 2026 639Views 0Likes

Health care may not have the meme-stock glamour of AI chips, but this spring the sector is quietly reminding investors why 'boring' can be beautiful. A trio of updates from Incyte (INCY), Pfizer (PFE) and Eupraxia Pharmaceuticals (NASDA: EPRX) is painting a…

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 688Views 0Likes

Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. A Chronic Disease Finally Meets a Long-Term Plan Eosinophilic…

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

by John F. Heerdink, Jr. March 2, 2026 678Views 0Likes

In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…

Tag: EOE

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

🚀 Register to Join “Food Shouldn’t Hurt: EoE, Eupraxia, and a Promising New Treatment Approach” – (Friday, August 21 at 8:30am PT)

The Million‑Patient Question: Is Eupraxia’s EP‑104GI Ready To Turn EoE Endoscopy Into A Business Model? -( $EPRX $SNY $XBI )

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY )

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

From Weekly Jabs to Yearly Scopes: Why Eupraxia’s EP‑104GI Might Have Sanofi Checking Its Calendar – ( $EPRX $SNY $XBI )

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

Your Guide To Staying Informed In The Markets